Clinical indications for newer antifungal agents.
Recent years have seen the release of multiple new systemic antifungal agents, significantly increasing options for the treatment of most serious fungal infections. Newly available drugs include those in the echinocandin class, including caspofungin, micafungin, and anidulafungin, as well as the newer generation triazoles, voriconazole and posaconazole. Ordering of these agents is variably restricted, depending on a given institution's policies, and all are costly. In this review we examine the available evidence and outline the role of newer antifungal medications in several common and/or important situations, including invasive and mucocutaneous Candida infection, febrile neutropenia, invasive aspergillosis, zygomycosis, and endemic mycoses.
Naeger-Murphy
Nina
N
Division of Infectious Diseases, Case Western Reserve University at MetroHealth Medical Center, Cleveland, Ohio 44109, USA.
Pile
James C
JC
D000935:Antifungal Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D001393:Azoles / Q000494:pharmacology / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D004358:Drug Therapy / Q000639:trends; D054714:Echinocandins / Q000494:pharmacology / Q000627:therapeutic use; D019353:Endemic Diseases; D006801:Humans; D009181:Mycoses / Q000145:classification / Q000188:drug therapy*; D009503:Neutropenia / Q000188:drug therapy; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D020096:Zygomycosis / Q000188:drug therapy
D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D014230:Triazoles